Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy

Molecular Cancer Therapeutics

Volumn 2, Issue 12, 2003, Pages 1361-1368

  Mohammad, Ramzi M ^a   Al Katib, Ayad ^a   Aboukameel, Amro ^a   Doerge, Daniel R ^b   Sarkar, Fazlul ^a   Kucuk, Omer ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISONE; VINCRISTINE;

ANIMAL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; DRUG EFFECT; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; MITOSIS; MOUSE; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DNA, NEOPLASM; DOXORUBICIN; G2 PHASE; GENISTEIN; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MICE; MICE, SCID; MITOSIS; NF-KAPPA B; PREDNISONE; VINCRISTINE;

EID: 4444237818     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002. (Pubitemid 34110469)
2. Armitage, J. O. and Weisenburger, D. D., For the Non-Hodgkin's Lymphoma Classification Project. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J. Clin. Oncol., 16: 2780-2795, 1998. (Pubitemid 28363044)
3. Elias, L., Portlock, C. S., and Rosenberg, S. A. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer, 42: 1705-1710, 1978. (Pubitemid 9053509)
4. Gordon, L. I., Harrington, D., Anderson, J., Colgan, J., Glick, J., Neiman, R., Mann, R., Resnik, G., Barcos, M., Gottlieb, A., and O'Connell, M. Comparison of second generation combination chemotherapeutic regimen (m-BACOD) with standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med., 327: 1342-1349, 1992.
5. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., Jr., and Miller, T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med., 328: 1002-1006, 1993. (Pubitemid 23095683)
6. Davis, R. E., Brown, K. D., Siebenlist, U., and Staudt, L. M. Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. JEM, 194: 1861-1883, 2001.
7. Siebenlist, U., Franzoso, G., and Brown, K. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol., 10: 405-455, 1994.
8. Neri, A., Change, C. C., Lombardi, L., Salina, M., Corradini, P., Maiolo, A. T., Chaganti, R. S., and Dalla-Favera, R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell, 67: 1075-1087, 1991. (Pubitemid 121001521)
9. Liou, H. C., Sha, W., Scott, M., and Baltimore, D. Sequential induction of NF-κB/Rel family proteins during B-cell terminal differentiation. Mol. Cell. Biol., 14: 5349-5359, 1994.
10. Miyamoto, S., Chiao, P., and Verma, I. Enhanced IκBα degradation is responsible for constitutive NF-κB activity in mature murine B-cell lines. Mol. Cell. Biol., 14: 3276-3282, 1994.
11. Lee, H., Arsura, M., Wu, M., Duyao, M., Buckler, A., and Sonenshein, G. Role of rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J. Exp. Med., 181: 1169-1177, 1995.
12. Adlercreutz, H., Honjo, H., and Higashi, A. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming traditional Japanese diet. Am. J. Clin. Nutr., 54: 1093-1100, 1991. (Pubitemid 21917676)
13. Adlercruetz, H., Markkanen, H., and Watanabe, S. Plasma concentrations of phytoestrogens in Japanese men. The Lancet, 342: 1209-1210, 1993. (Pubitemid 23331713)
14. Mills, P., Beeson, W., Philips, R., and Fraser, G. Cohort study of diet, lifestyle, prostate cancer in adventist men. Cancer, 64: 598-604, 1998.
15. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem., 262: 5592-5595, 1987.
16. Okura, A., Arakawa, H., Oka, H., Yoshinari, T., and Monden, Y. Effect of genistein on topoisomerase activity and on the growth of [val 12] Ha-ras transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun., 157: 183-189, 1998.
17. Fotsis, T., Pepper, M., Adlercreutz, H., Fleischman, G., Hase, T., Montesano, R., and Schweigerer, L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA, 90: 2690-2694, 1993. (Pubitemid 23113482)
18. Ruiz-Larrea, M., Mohan, A., Paganga, G., Miller, N., Bolwell, G., and Rice-Evans, C. Antioxidant activity of phytoestrogenic isoflavones. Free Radic. Res., 26: 63-70, 1997. (Pubitemid 27060130)
19. Kapiotis, S., Hermann, M., Held, I., Seelos, C., Ehringer, H., and Gmeiner, B. M. Genistein, the dietary-derived angiogenesis inhibitor prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler. Thromb. Vasc. Biol., 17: 2868-2874, 1997. (Pubitemid 28016034)
20. Kameoka, S., Leavitt, P., Chang, C., and Kuo, S. Expression of antioxidant properties in human intestinal Caco-2 cells treated with dietary isoflavonoids. Cancer Lett., 146: 161-167, 1999. (Pubitemid 29492885)
21. Davis, J. N., Kucuk, O., and Sarkar, F. H. Genistein inhibits NF-κβ activation in prostate cancer cells. Nutr. Cancer, 35: 167-174, 1999. (Pubitemid 30115128)
22. Davis, J. N., Kucuk, O., Djuric, Z., and Sarkar, F. H. Soy isoflavone supplementation in healthy men prevents NF-kB activation by TNF-α in blood lymphocytes. Free Radic. Biol. Med., 30: 1293-1301, 2001.
23. Li, Y. and Sarkar, F. H. Inhibition of NF κB activation in PC-3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res., 8: 2369-2377, 2002. (Pubitemid 34753612)
24. Haefner, B. NF-κB: arresting a major culprit in cancer. Drug Discov. Today, 7: 653-663, 2002.
25. Baldwin, A. S., Jr. The NF-kB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol., 14: 649-683, 1996.
26. Ghosh, S., May, M. J., and Kop, E. B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 16: 225-260, 1998. (Pubitemid 28183365)
27. Karin, M. and Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol., 18: 621-663, 2000. (Pubitemid 30365393)
28. Al-Katib, A. M., Smith, M. R., Kamanda, W. S., Pettit, G. R., Hamdan, M., Mohammad, A. N., Chelladurai, B., and Mohammad, R. M. Bryostatin 1 downregulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res., 4: 1305-1314, 1998. (Pubitemid 28213344)
29. Mohammad, R. M., Wall, N. R., Dutcher, J. A., and Al-Katib, A. M. The additional of Bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer Res., 6: 4950-4956, 2000. (Pubitemid 32110441)
30. Wall, N. R., Beck, F. W. J., Al-Katib, A., and Mohammad, R. M. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J. Drug Target., 9: 329-339, 2001. (Pubitemid 33094552)
31. Matsukawa, Y., Marui, N., Sakai, T., Satomi, Y., and Matsumoto, K. Genistein arrests cell progression at G2/M. Cancer Res., 53: 1328-1333, 1993.
32. Miayamoto, S. and Verma, I. M. Rel/NF-κB/IκB story. Adv. Cancer Res., 66: 255-287, 1995.
33. Beg, A. and Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science, 274: 782-784, 1996. (Pubitemid 26398258)
34. Davis, J. N., Kucuk, O., and Sarkar, F. H. Genistein inhibits NF-κh activation in prostate cancer cells. Nutr. Cancer, 35: 167-174, 1999. (Pubitemid 30115128)